Identify the molecules where your spend is concentrated but supplier alternatives are abundant. Procurement leverage, sized.
Twelve molecules in the warehouse fit the leverage profile in 2024. Niraparib carries seven active exporters and a Top-3 share of 91%, which means the buyer's spend concentrates on three names but ten alternatives exist for qualification. Olaparib, palbociclib, and ribociclib show similar shapes. Each is a category where the procurement team can drive a renegotiation by signalling readiness to redistribute spend across the broader exporter base.
| # | Molecule | Active exporters | Top-3 share | Lane HHI | Leverage |
|---|---|---|---|---|---|
| 1 | Niraparib | Oncology · PARP | 7 active exporters | Top-3 91% | NAI |
| 2 | Olaparib | Oncology · PARP | 25 active exporters | Top-3 72% | NAI |
| 3 | Palbociclib | Oncology · CDK4/6 | 9 active exporters | Top-3 86% | NAI |
| 4 | Ribociclib | Oncology · CDK4/6 | 8 active exporters | Top-3 88% | NAI |
| 5 | Abemaciclib | Oncology · CDK4/6 | 15 active exporters | Top-3 79% | NAI |
Your active sourcing book. Default uses the supply-side spend cube; ERP upload sharpens the spend numbers but is not required.
Spend concentration (your top supplier's share of the category) versus supplier fragmentation (the count of active exporters on the lane). High concentration × broad alternatives equals leverage.
Citation-anchored brief with the leverage candidates ranked, the alternative supplier shortlist per molecule, and a one-click hand-off to the dual-source workflow.
Spend concentration alone is risk. Spend concentration with abundant alternatives is leverage. The combined score reads the procurement position correctly.
Each leverage candidate carries a pre-built list of the next-tier suppliers ready to compete on the category. Activates the credible-alternative posture at renewal.
The AI agent recommends a target spend cap per supplier (typically 40-50% of category) to preserve leverage. Above the cap, the category locks in; below, the negotiation stays open.
When a major contract is within 90 days of renewal and the molecule sits in the leverage candidate list, the brief fires automatically with the renegotiation pack pre-built.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve molecules with mid-to-high spend concentration and 5+ alternative exporters · count is active exporters on the molecule's largest lane.
The leverage analysis is the negotiation playbook on top of the spend cube. PharmaDB joins spend concentration to alternative-supplier count, surfaces categories where leverage exists, and pre-builds the renegotiation brief. The view is lane_competitiveness; the join is to company_trade_exports_by_molecule for the alternatives count.
Spend concentration above 30% in a single supplier combined with at least five alternative active exporters on the same lane. The pattern means your spend is concentrated by choice (not by necessity) and a credible threat of redistribution exists.
Olaparib has 25 active exporters across the lane footprint; niraparib has seven. The alternatives pool is the negotiation lever. More alternatives, more leverage, simpler renegotiation.
The spend cube is the static spend inventory. The leverage analysis is the action layer on top: it identifies where the buyer can act on the spend pattern. Both run on the same underlying tables.
Not for the leverage signal itself: the supplier-side spend cube and lane HHI give the concentration picture. ERP upload sharpens the buyer-side spend concentration and improves the renegotiation savings estimate.
Concentrated spend with thin alternatives is supplier leverage, not buyer leverage. The brief surfaces it on a separate page (Lane Concentration Risk) and triggers a dual-source qualification workflow rather than a renegotiation.
Trade aggregates refresh weekly. Leverage metrics recompute on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.